Biosimilar Insulin Products in the US to Grow at a CAGR of 74

Percent over the Period 2013-2020

Lantus is expected to be the most lucrative target for biosimilar manufacturers and

account 71% of the total biosimilar Insulin sales by 2020.

A study undertaken by IMARC Group entitled "Biosimilar/Follow-on Biologics Market

Report & Forecast: A Focus on the US (2011-2020)" reveals that biosimilar Insulin

products in the US will grow at a CAGR of 74% during 2013-2020. Findings from the

study suggest that currently three Insulin brands are expected to face biosimilar

competition during 2013-2020. Eli Lilly’s Humalog (Insulin Lispro) is expected to be

the first drug to face biosimilar competition in 2013. Humalog is expected to be

followed by Sanofi’s Lantus (Insulin Glargine) and Novo Nordisks Levemir (Insulin

Detemir). The report has done a comprehensive long range forecast for each of the

three products and expects Lantus to be the most lucrative target for biosimilar

manufacturers and account 71% of the total biosimilar Insulin sales by 2020.

IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A

Focus on the US (2011-2020)” provides an analytical and statistical insight into the US

biosimilar market. The study, that has been undertaken using desk-based as well as

qualitative primary research, provides and draws upon analysis of six aspects of the

US biosimilar market.

Key Aspects Analyzed:

Evaluating the Current Market Landscape of Biosimilars:

Identification of currently marketed biosimilars and their historical performance

Identifying the reasons for the slow uptake of currently marketed biosimilars

Analyzing historical data to formulate conclusions on the future growth and market

trends of biosimilars

imarc© 1

Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:

Analyzing historical time series data on price, volume and sales erosion in the US &

Europe

Analyzing previous models and assumptions on price and volume erosion caused by

biosimilars

Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by

small molecule generics

Evaluating and comparing price, volume and sales erosion by biosimilars across various

biological classes

Evaluating the Market Potential of Biosimilars Across Various Molecules:

Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa

(Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog),

Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon

Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab

(Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab

(Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and

Natalizumab (Tysabri).

Focus of the Analysis for Each Molecule:

Historical background and overview

Historical brand sales

Patent position

Competing products

Biosimilars in pipeline

Brand and biosimilar sales forecasts

Evaluating the Sales of Biosimilars across Various Indications:

Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and

Growth Deficiency

Focus of the Analysis for Each Indication:

Historical brand sales

Brand and biosimilar sales forecasts

Indication wise breakup of molecules

imarc© 2

Evaluating the Biosimilar Competitive Landscape:

Identifying branded biological manufacturers that expect the highest amount of erosion

from biosimilars

Identifying biosimilar manufacturers and their pipelines

Understanding the Current Legislation on Biosimilars:

An insight into the Biologics Price Competition and Innovation Act

An insight into the key biosimilar issues that still remain unaddressed

Interchangeability and Substitutability

Data Exclusivity

Statutory provisions for dealing with patent litigations

To buy the complete report or to get a free sample, please contact:

IMARC Group AsiaEmail: apac@imarcgroup.comPhone: +91-120-425-6531

IMARC Group North America Email:  america@imarcgroup.comPhone: +1-631-791-1145

To know more please visit: http://www.imarcgroup.com/

Key words

Biosimilar market, biosimilar industry, follow-on biologics market, biogenerics market, us biosimilar

market, biosimilar volume penetration rate

imarc© 3